About us

Philippe Lambin is a Clinician, Radiation Oncologist, “ERC advanced & twice ERC PoC grant laureate” respectively from 2016, 2017 & 2020 and pioneer in translational research with a focus on tumour hypoxia and Decision Support Systems.

He holds a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Precision Medicine & Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”, until 2011).

He is co-author of more than 526 peer reviewed scientific papers (h-index 127  Google scholar), co-inventor of more than 20 patent families (filed or submitted) of which 10 are in the (pre)commercialization phase and (co) promoter of more than 60 completed PhD’s (2 with cum laude). Prof. P. Lambin also has extensive experience with clinical trials.

He is one of the co-inventor of “Radiomics”, “Clinical Decision Support Systems”, “Distributed learning” from federated databases, genetically modified bacteria for cancer treatment, the combination of immunocytokines with radiation and Lymphocytes-Sparing Radiotherapy (LSRT).

Ludwig Dubois is Full Professor and Chair of Experimental and Translational Radiobiology at the Manchester Cancer Research Centre (University of Manchester) and a Guest Scientist at Maastricht University, where he spent 20+ years building his work on tumour hypoxia.

An expert in the preclinical biology of hypoxia with 90+ publications on the subject (h-index 52), he leads Convert’s preclinical strategy and biomarker science as CSO. He holds a Ph.D. and an MSc in Biomedical Sciences (KU Leuven).

Jan Theys is Professor of Precision Oncology and Head of Department at Maastricht University, where he also serves as Director of Education for Biomedical Sciences. He specialises in prokaryotic living medicine, the tumour microenvironment, and tumour metabolism, with 20+ years of research experience and an extensive publication record (h-index 41).

He has been Convert’s Chief Technology Officer since 2021, driving the company’s technology platform. He holds a Ph.D. from KU Leuven (Rega Institute).

Amélie Vanneste is a Clinical Project Manager with 15+ years in clinical research across biotech and big pharma (Baxter, iTeos, Celyad Oncology, PAREXEL). She has led Phase I to IV studies across Europe, the US and India, managing CROs, vendors, sites, budgets and timelines end to end, with hands-on expertise in the new EU CTR/CTIS framework.

At Convert she leads the operational coordination of the CP-506 clinical programme. She holds a Master in Health Care Management & Policy (Ghent) and a Master in Physiotherapy (VUB).

Antoine Sparenberg is Convert’s Chief Operating Officer.  Over 7+ years he has worked across management consulting and venture-backed startups, including co-founding and running operations at early-stage ventures. He holds a Master in International Business (CEMS / Louvain School of Management) and a Bachelor in Business Engineering (UCLouvain).

At Convert he leads day-to-day operations and oversees corporate governance.

Hélène Devroye is an experienced clinical project manager with deep GCP and GMP knowledge, advising on the clinical development of Convert’s CP-506 programme. She embeds best industry practice to safeguard patient safety and the quality and reliability of trial data.